Clinical Trials List
2026-05-01 - 2027-12-31
Phase II
Recruiting8
A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat
-
Trial Applicant
-
Sponsor
Caliway Biopharmaceuticals Co., Ltd
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/08/30
Investigators and Locations
Co-Principal Investigator
- Donald Liu Division of Dermatology
- 黃怡璇 Division of Dermatology
- 陳彥廷 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HSIAO-CHEN LEE Division of Plastic Surgery
- 賴雅薇 Division of Plastic Surgery
- 吳益嘉 Division of Plastic Surgery
- 陳威宇 Division of Plastic Surgery
- 張兆瑋 Division of Plastic Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 許士杰 Division of Plastic Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李昀璋 Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- BANG-BIN CHEN Division of Radiology
- YI-HUA LIAO Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 黃彥綾 Division of Radiology
- Chung-Yao Hsu Division of Dermatology
- Chun-Bing Chen Division of Dermatology
- Yu-Huei Huang Division of Dermatology
- Chin-Yi Yang Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
RSV-0
Dosage Form
Dosage
Endpoints
•Mean percentage change from Baseline in abdominal SC fat volume measured by MRI at 4 weeks after final treatment in the CBL-514 group versus the placebo group
Stage 2:
•Percentage change of abdominal SC fat volume as measured by MRI at 4 weeks after the final treatment compared with individual Baseline
Inclution Criteria
Male or female, aged ≥ 18 years old.
Body mass index (BMI) > 18.5 and < 30 kg/m2 and body weight ≥ 50 kg.
CR-AFRS and PR-AFRS score: participant has greater than Grade 1 abdominal fat as assessed both by the Investigator on the CR-AFRS and by the participant on the PR-AFRS.
Participant maintained a stable lifestyle.
Voluntarily signs the Informed Consent Form and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to study procedures.
Participant has complied with Stage 1 study procedures and requirements.
Exclusion Criteria
Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive method and refraining from ova donation from the time of Screening and throughout the study until 90 days after the last dose of IP, or who is currently pregnant or lactating. Fertile male participant who is not willing to commit to an acceptable contraceptive method and refraining from sperm donation from the time of the first dose of IP and throughout the study until 90 days after the last dose of IP.
Participant was diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications.
Participant has delayed wound healing or poorly controlled diabetes.
Participant has a history of active malignancy within 3 years before Screening, or is currently being evaluated for a possible malignancy.
Participant has a history of trypanophobia, the extreme fear of medical procedures involving injections or needles.
Participant has a visible Panniculus (folding fat) or visible folds of skin on the abdomen in a standing position.
Participant has severe or very severe abdominal visceral fat.
Participant has skin conditions which, in the opinion of the Investigator, would pose a risk to the participant if receiving the IP or interfere with the safety or efficacy evaluation.
Participant has undergone the following procedures: a. Surgery that caused scar tissue at the treatment area; b. Previous history of abdominoplasty or abdominal liposuction within the treatment area; c. Aesthetic procedure for body contouring or fat reduction at the treatment area within 12 months before Screening; d. SC injection or transdermal application of medication at the treatment area within 4 weeks before Screening.
Participant with contraindications to magnetic resonance imaging (MRI).
Participant is on prescription or over-the-counter weight reduction medication, weight reduction programs, or taking oral or injectable GLP-1 agonists (eg, semaglutide, tirzepatide, liraglutide, etc.) within 6 months before Screening.
Participant is undergoing long-term systemic steroid or immunosuppressive therapy.
Participant is taking or will take any medication that is a known strong inhibitor or inducer of CYP1A2 enzymes, sensitive CYP1A2 substrates, or medication with narrow therapeutic index during the study that, in the opinion of the Investigator, may affect the safety or efficacy evaluation of the IP or pose undue risk to the participant.
Participant with history of hypersensitivity to local anesthesia (eg, lidocaine).
Participant with known allergies or significant adverse reaction to the IP or any of its ingredients.
Participant with liver cirrhosis or abnormal liver function test at Screening.
Participant currently on dialysis or with any renal impairment at Screening.
Participant has received any investigational product (including a device) within 3 months before Screening.
Participant has an unstable condition (eg, psychiatric disorder, history of substance abuse within 3 years before Screening) or is otherwise thought to be unreliable or incapable of complying with the requirements of the protocol (eg, visit schedule, off-site MRI measurement).
Participant with a known history or current diagnosis of body dysmorphic disorder or eating disorders.
Participant has a history of vasovagal syncope.
The Estimated Number of Participants
-
Taiwan
200 participants
-
Global
250 participants
